Treatment
tumor, JGCA, gastric cancer
TUMOR, CAVITY, GASTRIC CANCER
All patients were randomly assigned to the HIPEC group or non-HIPEC group after radical gastrectomy using a web response system. Patients in the HIPEC group received HIPEC treatment and systemic chemotherapy, while patients in the non-HIPEC group received only systemic chemotherapy. The treatment schedule of this study is shown in Fig. Surgical treatmentTreatment schedule for advanced gastric cancer patients randomized into the HIPEC group and the non-HPIEC groupAll patients received open or laparoscopic surgery, and distal or total gastrectomy was selected depending on the tumor location. Routine D2 lymph-node dissections were performed according to the Japanese gastric cancer treatment guidelines (fourth edition) (JGCA HIPECFor the patients allocated to the HIPEC group, two inflow catheters were inserted into the upper abdomen, and two outflow catheters were inserted into the pelvic cavity. The HIPEC treatment was conducted twice within 72 h after gastrectomy. Generally, the first HIPEC treatment was performed within 24 h after surgery followed by the second HIPEC at an interval of 24–48 h. Approximately 3 L of heated normal saline containing cisplatin (40 mg/mPostoperative systemic chemotherapyPostoperative systemic chemotherapy based on the SOX regimen (6–8 cycles of S-1 combined with oxaliplatin) was administered to patients in both groups 4–6 weeks after radical surgery. Oxaliplatin (130 mg/m